The earnings call reflects a strong financial performance and promising clinical trial results, particularly for EPKINLY and Rina-S. The company is strategically investing in its pipeline and expanding its market presence. However, challenges such as the discontinuation of HexaBody-OX40 and potential regulatory hurdles were noted.

Company Guidance -

Q3 2025

During the Genmab First Half 2025 Financial Results Conference Call, key guidance metrics included a 19% growth in total revenue, a 56% increase in operating profit, and an end-of-period cash reserve of around $3 billion. The company completed a share buyback in June, indicating confidence in its future. Notably, Genmab's late-stage pipeline is progressing, with the FDA granting priority review to their sBLA for epcoritamab in second-line follicular lymphoma, which could make it the first bispecific antibody combination available for this indication. The EPCORE FL-1 study showed a 79% reduction in disease progression or death risk. EPKINLY sales reached $211 million, a 74% increase year-over-year, contributing to a 31% share of total revenue growth alongside Tivdak. Genmab also raised its 2025 revenue guidance to $3.5 to $3.7 billion, reflecting a 15% growth at the midpoint, with recurring revenues anticipated to grow by 22%.

Strong Financial Performance

Total revenue grew by 19%, with operating profit increasing by 56%. Recurring revenue also rose by 27%, driven by strong product sales from EPKINLY and Tivdak.

Positive Phase III EPCORE-FL1 Trial Results

The EPCORE-FL1 trial met its dual primary endpoints, reducing the risk of disease progression or death by 79%. This supports global regulatory submissions and highlights the potential to transform treatment paradigms.

Continued Commercial Success

EPKINLY and Tivdak sales grew by 60% year-over-year, contributing 31% of total revenue growth. EPKINLY posted a 74% increase in global sales.

Expanded Pipeline and Strategic Investments

The company is investing in high-impact programs with plans for additional Phase III trials for Rina-S and evaluating acasunlimab in advanced melanoma.

Improved 2025 Financial Guidance

Revenue guidance increased to $3.5 billion to $3.7 billion, reflecting a robust 15% growth at the midpoint.

Genmab (GMAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GMAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.44 / -	0.287	―	―	―
Aug 07, 2025	2025 (Q2)	0.40 / 0.54	0.317	70.98% (+0.23)
May 08, 2025	2025 (Q1)	0.23 / 0.30	0.292	4.45% (+0.01)
Feb 12, 2025	2024 (Q4)	0.37 / 0.85	0.139	512.23% (+0.71)
Nov 06, 2024	2024 (Q3)	0.31 / 0.29	0.464	-38.15% (-0.18)
Aug 08, 2024	2024 (Q2)	0.31 / 0.32	0.305	3.93% (+0.01)
May 02, 2024	2024 (Q1)	0.19 / 0.29	0.05	484.00% (+0.24)
Feb 14, 2024	2023 (Q4)	0.31 / 0.14	0.125	11.20% (+0.01)
Nov 07, 2023	2023 (Q3)	0.33 / 0.46	0.528	-12.12% (-0.06)
Aug 03, 2023	2023 (Q2)	0.29 / 0.30	0.399	-23.56% (-0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GMAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$21.51	$22.69	+5.49%
May 08, 2025	$20.60	$19.42	-5.73%
Feb 12, 2025	$18.89	$19.69	+4.24%
Nov 06, 2024	$22.75	$22.33	-1.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Genmab A/S (GMAB) report earnings?

Genmab A/S (GMAB) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Genmab A/S (GMAB) earnings time?

Genmab A/S (GMAB) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GMAB EPS forecast?

GMAB EPS forecast for the fiscal quarter 2025 (Q3) is 0.44.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing